Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : American Bio Medica (ABMC) drug test solution -taking off! -- Ignore unavailable to you. Want to Upgrade?

To: David L. Wasylenko who wrote (601)	1/17/2001 9:02:19 PM
From: Barbara Hospel	Read Replies (2) \| Respond to of 629

Nothing has happened for a long time with this stock. Only recently has it seen some action. It had a correction today. It seems to me that there is a future for their product.

To: David L. Wasylenko who wrote (601)	5/30/2001 12:41:54 PM
From: Skywatcher	Respond to of 629

American Bio Medica Signs Major Deal With Northwest Drug Testing Companies Reach Agreement to Offer Rapid Drug Screen to NDT Customers KINDERHOOK, N.Y.--(BUSINESS WIRE)--May 21, 2001-- American Bio Medica Corporation (NASDAQ: ABMC - news) today announced it has signed an agreement to provide Rapid Drug Screen(TM) assays to Northwest Drug Testing (NDT), a division of NWT Inc., and one of the world's foremost leaders in drugs of abuse and adulterant testing. The six-figure deal covers purchases of ABMC products within the next year, with options for further increases in the following years. Rapid Drug Screen will be offered to NDT customers to complement the Salt Lake City-based laboratory's extensive array of drugs of abuse testing services. With Rapid Drug Screen, NDT can offer on-site drug testing resources that feature ease of sample collection and testing with quick turnaround of results. For positive on-site test results NDT can provide necessary confirmation testing services through its SAMHSA-certified laboratory. According to Michael Feldman, Ph.D., General Manager and Sr Vice President of NDT, the agreement further positions NDT as the preeminent drug testing resource to serve its customer base. Looks like they aren't so dead right now. chris